Bifeprunox

Its experimental schizophrenia drug, bifeprunox, which is still being tested in Europe, was rejected by the Food and Drug Administration in the U.S. and Solvay last year abandoned development of an obesity drug. ❋ Unknown (2009)

The FDA is "establishing monopolies" by rejecting drugs just because they're inferior to existing ones growled outgoing Wyeth CEO Bob Essner when bifeprunox was not approved. ❋ Unknown (2008)

Last year it rejected Wyeth's osteoporosis drug, bazedoxifene, because of stroke and blood clot problems, schizophrenia drug, bifeprunox, because it was not as effective as other drugs on the market and menopause drug, Pristiq, because of serious heart or liver complications experienced by trial participants. ❋ Unknown (2008)

The approval is a rare piece of good news in a run of misfortunes for Wyeth, including the FDA's rejection of Wyeth's schizophrenia drug bifeprunox. ❋ Unknown (2008)

Last year, the FDA rejected the company's schizophrenia drug bifeprunox, and delayed approval of its osteoporosis drug Viviant because of safety and data concerns. ❋ Unknown (2008)

The FDA rejected Wyeth's application for approval of bifeprunox, a proposed medication developed in partnership with Solvay Pharmaceuticals Inc. ❋ Unknown (2008)

Not only has it failed to approve three new Wyeth drugs designed to replace Effexor revenues when its patent expires in 2010 -- Viviant, for osteoporosis, Pristiq, for depression and menopause and bifeprunox for schizophrenia -- it dared to compare their benefit/risk profile to drugs already on the market, challenging the Pharma received wisdom that newer equals better. ❋ Unknown (2007)

Wyeth is expected to file for approval of bifeprunox for schizophrenia and bazedoxifene for osteoporosis in the near term. ❋ Unknown (2006)

Effexor lose patent protection by 2011, bifeprunox and Pristiq have been plagued by issues / slow uptake and will probably never reach the combined $4B in projected sales. ❋ Unknown (2009)

Lundbeck and Solvay Pharmaceuticals, B.V. have initiated two Phase III clinical trials with bifeprunox for maintenance treatment of schizophrenia. ❋ Unknown (2009)